ReiThera Srl, The Ragon Institute and IAVI collaborating to advance a GRAd-based T Cell HIV vaccine towards clinic

ReiThera Srl, the Ragon Institute, and IAVI announced a collaboration to develop a novel HIV vaccine candidate. The vaccine will be composed of ReiThera’s Gorilla adenoviral (GRAd) vector and HIV T cell epitopes identified by the Ragon Institute, with IAVI sponsoring and conducting a phase I clinical trial. The project is being funded by the Bill & Melinda Gates Foundation.

ReiThera is a contract development manufacturing organization (CDMO) focused on technology and process development and GMP manufacturing for advanced therapies and genetic vaccines. Under the collaboration, ReiThera will perform vector engineering and generation, process development, and good manufacturing practice (GMP) manufacture and release for the clinical use of GRAd-HIV vaccine.